O-2372

O-2372 is a psychoactive drug and research chemical that acts as a selective cannabinoid receptor agonist. It is part of the AM series of cannabinoids discovered by Alexandros Makriyannis at Northeastern University.

Chemistry

O-2372 is a derivative of cannabidiol, a natural component of cannabis. It is structurally related to other synthetic cannabinoids such as AM-2201 and JWH-018, but it has a unique chemical structure that distinguishes it from these other compounds.

Pharmacology

O-2372 acts as a full agonist at the CB1 receptor and the CB2 receptor, the two main types of cannabinoid receptors in the body. It has a high binding affinity for these receptors, which means it can produce strong effects even at low doses. The exact mechanism of action of O-2372 is not fully understood, but it is thought to work by mimicking the effects of naturally occurring endocannabinoids in the body.

Effects

The effects of O-2372 can vary depending on the dose and the individual's sensitivity to cannabinoids. Common effects include euphoria, relaxation, altered perception, and increased appetite. However, O-2372 can also cause unwanted side effects such as anxiety, paranoia, and psychosis in some individuals, especially at high doses.

Legal Status

The legal status of O-2372 varies by country. In some countries, it is classified as a controlled substance, while in others it is legal to possess and use. It is important to note that even in countries where O-2372 is legal, it may still be illegal to sell or distribute it without a license.

Research

O-2372 is used in scientific research to study the endocannabinoid system and the effects of cannabinoids on the body. It is also used as a reference compound in the development of new cannabinoid drugs.

See Also

• Cannabinoid
• Cannabidiol
• AM-2201
• JWH-018
• Endocannabinoid system